Antisense antibacterials

Bibliography

• WAGNER EG, ALTUVIA S, ROMBY P: Antisense RNAs in bacteria and their genetic elements. Adv. Genet. (2002) 46:361–398.
   Google Scholar
• DAVIES J: Inactivation of antibiotics andthe dissemination of resistance genes.Science (1994) 264(5157):375–382.
   PubMed Web of Science ®Google Scholar
• •Describes the origins and spread of antibacterial resistance traits.
   Google Scholar
• GILLESPIE SH: Antibiotic resistance in the absence of selective pressure. Int. Antimicrob. Agents (2001) 17 (3) :171–176.
   PubMedGoogle Scholar
• •Indicates that resistance traits are likely to persist in the clinic.
   Google Scholar
• TSIODRAS S, GOLD HS, SAKOULAS G et al.: Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet (2001) 358(9277):207–208.
   PubMed Web of Science ®Google Scholar
• MURRAY RW, SCHAADT RD, ZURENKO GE, MAROTTI KR: Ribosomes from an oxazolidinone-resistant mutant confer resistance to eperezolid in a Staphylococcus aureus cell-free transcription- translation assay. Antimicrob. Agents Chemother. (1998) 42(4):947–950.
   PubMedGoogle Scholar
• ORR RIVI:Technology evaluation: fomivirsen, Isis Pharmaceuticals Inc/CIBA vision. Carr. Opin. Mol. Ther. (2001) 3(3):288–294.
   PubMedGoogle Scholar
• NIKAIDO H: Prevention of drug access to bacterial targets: permeability barriers and active efflux. Science (1994) 264(5157):382–388.
   PubMed Web of Science ®Google Scholar
• ORR RIVI, O'NEILL CF: Patent review: therapeutic applications for antisense oligonucleotides 1999-2000. Curt: Opin. Mol. Ther. (2000) 2(3):325–331.
   PubMedGoogle Scholar
• TANIGUCHI T, WEISSMANN C: Inhibition of Qbeta RNA 70S ribosome initiation complex formation by an oligonucleotide complementary to the 3' terminal region of E coli 16S ribosomal RNA. Nature (1978) 275(5682):770–772.
   PubMedGoogle Scholar
• •Early evidence for the potential for antisense antibaterials.
   Google Scholar
• RAHMAN MA, SUMMERTON J, FOSTER E et al.: Antibacterial activity and inhibition of protein synthesis in Escherichia coli by antisense DNA analogs. Antisense Res. Dev. (1991) 1(4):319–327.
   PubMedGoogle Scholar
• WHITE DG, MANEEWANNAKUL K, VON HOFE E et al.: Inhibition of the multiple antibiotic resistance (mar) operon in Escherichia coli by antisense DNA analogs. Antimicrob. Agents Chemother. (1997) 41(12):2699–2704.
   Google Scholar
• HARTH G, ZAMECNIK PC, TANG JY, TABATADZE D, HORWITZ MA: Treatment of Mycobacterium tuberculosis with antisense oligonucleotides to glutamine synthetase mRNA inhibits glutamine synthetase activity, formation of the poly-L-glutamate/glutamine cell wall structure and bacterial replication. Proc. Nati Acad. St". USA (2000) 97(1):418–423.
   Google Scholar
• FILLION P, DESJARDINS A, SAYASITH K, LAGACE J: Encapsulation of DNA in negatively charged liposomes and inhibition of bacterial gene expression with fluid liposome-encapsulated antisense oligonucleotides. Biochim. Biophys. Acta. (2001) 1515(1):44–54.
   PubMed Web of Science ®Google Scholar
• •Shows that antisense antibacterials can be improved by formulation.
   Google Scholar
• GOOD L, NIELSEN PE: Inhibition of translation and bacterial growth by peptide nucleic acid targeted to ribosomal RNA. Proc. Natl. Acad. Sci. USA (1998) 95 (5)2073–2076.
   Google Scholar
• GOOD L, NIELSEN PE: Antisense inhibition of gene expression in bacteria by PNA targeted to mRNA. Nat. Biotechnol. (1998) 16(4):355–358.
   PubMed Web of Science ®Google Scholar
• GOOD L, SANDBERG R, LARSSON O, NIELSEN PE, WAHLESTEDT C: Antisense PNA effects in escherichia coli are limited by the outer- membrane LPS layer. Microbiology (2000) 146(10):2665–2670.
   PubMedGoogle Scholar
• NIELSEN PE: Peptide nucleic acids as antibacterial agents via the antisense principle. Expert Opin. Investig. Drugs (2001) 10(2):331–341.
   PubMed Web of Science ®Google Scholar
• GOOD L, AWASTHI SK, DRYSELIUS R, LARSSON O, NIELSEN PE: Bactericidal antisense effects of peptide-PNA conjugates. Nat. Biotechnol. (2001) 19(4):360–364.
   PubMed Web of Science ®Google Scholar
• •Shows bacterial killing by antisense effects without apparent harm to human cells.
   Google Scholar
• ERIKSSON M, NIELSEN PE, GOOD L: Cell permeabilization and uptake of antisense peptide-peptide nucleic acid (PNA) into Escherichia coli. I Biol. Chem. (2002) 277(9):7144–7147.
   Google Scholar
• •Shows that antisense peptide-PNAs can permeabilise bacteria.
   Google Scholar
• HANCOCK RE: Peptide antibiotics. Lancet (1997) 349(9049):418–422.
   PubMed Web of Science ®Google Scholar
• SUMMERTON J, WELLER D: Morpholino antisense oligomers: design, preparation and properties. Antisense Nucleic Add Drug Dev. (1997) 7(3):187–195.
   PubMedGoogle Scholar
• MORCOS PA: Achieving efficient delivery of morpholino oligos in cultured cells. Genesis (2001) 30(3):94–102.
   PubMedGoogle Scholar
• CRAIG A, VANSTONE D, AGRAWAL S: Patent strategies in the antisense oligonucleotide based therapeutic approach. Expert Opin. Ther. Patents (1997) 7(10):1175–1182.
   Web of Science ®Google Scholar
• TAN YT, TILLETT DJ, MCKAY IA: Molecular strategies for overcoming antibiotic resistance in bacteria. Mol. Med. Today (2000) 6(8):309–314.
   PubMedGoogle Scholar
• ISLAM A, HANDLEY SL, THOMPSON KS, AKHTAR S: Studies on uptake, subcellular trafficking and efflux of antisense oligodeoxynucleotides in glioma cells using self-assembling cationic lipoplexes as delivery systems. Drug Target. (2000) 7(5):373–382.
   PubMedGoogle Scholar
• LI B, HUGHES JA, PHILLIPS MI: Uptake and efflux of intact antisense phosphorothioate deoxyoligonucleotide directed against angiotensin receptors in bovine adrenal cells. New-or/um. Int. (1997) 31(3):393–403.
   Google Scholar